Rosmantuzumab
Monoclonal antibody
- none
- 1684393-04-1
- none
- VD026R6TCI
- D11369
Rosmantuzumab (INN;[1] development code OMP-131R10) is a humanized monoclonal antibody designed for the treatment of cancer.[2][3][4]
This drug was developed by OncoMed Pharmaceuticals.[5]
References
- ^ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information. 30 (2).
- ^ Katoh M (August 2018). "Multi‑layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/β‑catenin signaling activation (Review)". Int. J. Mol. Med. 42 (2): 713–725. doi:10.3892/ijmm.2018.3689. PMC 6034925. PMID 29786110.
- ^ Katoh M (November 2017). "Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review)". Int. J. Oncol. 51 (5): 1357–1369. doi:10.3892/ijo.2017.4129. PMC 5642388. PMID 29048660.
- ^ Katoh M, Katoh M (September 2017). "Molecular genetics and targeted therapy of WNT-related human diseases (Review)". Int. J. Mol. Med. 40 (3): 587–606. doi:10.3892/ijmm.2017.3071. PMC 5547940. PMID 28731148.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Rosmantuzumab, American Medical Association.
- v
- t
- e